Salarius Pharmaceuticals (SLRX)
(Delayed Data from NSDQ)
$0.50 USD
0.00 (-0.78%)
Updated Apr 26, 2024 03:58 PM ET
After-Market: $0.48 -0.02 (-3.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Salarius Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 2 | 5 | 3 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 2 | 5 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 13 | 32 | 15 | 13 | 12 |
Income After Depreciation & Amortization | -13 | -32 | -13 | -8 | -8 |
Non-Operating Income | 0 | 0 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -13 | -32 | -13 | -7 | -7 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -13 | -32 | -13 | -7 | -7 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -13 | -32 | -13 | -7 | -7 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -13 | -32 | -13 | -8 | -8 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -13 | -32 | -13 | -8 | -8 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.27 | 2.13 | 1.66 | 0.62 | 0.13 |
Diluted EPS Before Non-Recurring Items | -3.84 | -10.71 | -7.75 | -12.50 | -53.00 |
Diluted Net EPS (GAAP) | -3.84 | -14.88 | -7.75 | -12.50 | -53.00 |
Fiscal Year end for Salarius Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.97 | 2.54 | 3.97 | 5.43 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -0.97 | -2.54 | -3.97 | -5.43 |
Non-Operating Income | NA | 0.09 | 0.09 | 0.09 | 0.08 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -0.88 | -2.44 | -3.88 | -5.34 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -0.88 | -2.44 | -3.88 | -5.34 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -0.88 | -2.44 | -3.88 | -5.34 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 3.27 | 3.75 | 2.71 | 2.39 |
Diluted EPS Before Non-Recurring Items | NA | -0.22 | -0.65 | -1.43 | -2.23 |
Diluted Net EPS (GAAP) | NA | 0.47 | -0.65 | -1.43 | -2.23 |